Juno Therapeutics Inc. shares surged 46% in their market debut Friday, after a flurry of demand for the year’s last expected new offering led the biotech firm to price above its already-boosted range. . Juno, which develops cancer treatments that use the body’s own immune system to fight the disease, began trading Friday on the Nasdaq at $39 a share, after pricing 11 million shares at $24.. Shares...
  